BiperidenAnticholinergic drug CAS# 514-65-8 |
- Sulfo-NHS-Biotin
Catalog No.:BCC3576
CAS No.:119616-38-5
- Sulfo-NHS-LC-Biotin
Catalog No.:BCC3578
CAS No.:127062-22-0
- Biotin-HPDP
Catalog No.:BCC3583
CAS No.:129179-83-5
- NHS-SS-Biotin
Catalog No.:BCC3581
CAS No.:142439-92-7
- Sulfo-NHS-SS-Biotin
Catalog No.:BCC3580
CAS No.:325143-98-4
- NHS-LC-Biotin
Catalog No.:BCC3579
CAS No.:72040-63-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 514-65-8 | SDF | Download SDF |
| PubChem ID | 2381 | Appearance | Powder |
| Formula | C21H29NO | M.Wt | 311.46 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | KL 373 | ||
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol | ||
| SMILES | C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O | ||
| Standard InChIKey | YSXKPIUOCJLQIE-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Biperiden(KL 373) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker.
Target: M1 receptors
Biperiden is an antiparkinsonian agent of the anticholinergic type. It is used for the adjunctive treatment of all forms of Parkinson's disease (postencephalitic, idiopathic, and arteriosclerotic)[1]. Biperiden has an atropine-like blocking effect on all peripheral structures which are parasympathetic-innervate. It also has a prominent central blocking effect on M1 receptors [2].
Biperiden (0.11 mg/kg), benactyzine (0.3 mg/kg),caramiphen (10 mg/kg), procyclidine (3 mg/kg), and trihexyphenidyl (0.12 mg/kg) separately and each in combination with physostigmine (0.1 mg/kg) is to make a comparative assessment of potential cognitive effects. The results showed that benactyzine, caramiphen, and trihexyphenidyl reduced rats' innate preference for novelty, whereas biperiden and procyclidine did not [3].
Clinical indications: parkinsonism
FDA Approved Date:
Toxicity: Drowsiness; vertigo; headache; dizziness References: | |||||
Biperiden Dilution Calculator
Biperiden Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.2107 mL | 16.0534 mL | 32.1069 mL | 64.2137 mL | 80.2671 mL |
| 5 mM | 0.6421 mL | 3.2107 mL | 6.4214 mL | 12.8427 mL | 16.0534 mL |
| 10 mM | 0.3211 mL | 1.6053 mL | 3.2107 mL | 6.4214 mL | 8.0267 mL |
| 50 mM | 0.0642 mL | 0.3211 mL | 0.6421 mL | 1.2843 mL | 1.6053 mL |
| 100 mM | 0.0321 mL | 0.1605 mL | 0.3211 mL | 0.6421 mL | 0.8027 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Biperiden is an anticholinergic drug [1].
As an anticholinergic drug, biperiden is first used in the treatment of Parkinson's disease. It is a competitive antagonist of muscarinic receptor. It has been believed that in the patients of PD, a reduction of intranigral dopamine concentrations results in a relative imbalance between the dopaminergic and cholinergic neurological pathways. The anticholinergics can correct the imbalance through reducing the degree of neurotransmission mediated by neostriatal acetylcholine. Biperiden is also used to treat extrapyramidal side effects of antipsychotic drugs. In addition, the misuse of biperiden causing delirium has been reported in several clinical settings [1, 2].
References:
[1] Brocks D R. Anticholinergic drugs used in Parkinson’s disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci, 1999, 2(2): 39-46.
[2] Espi Martinez F, Espi Forcen F, Shapov A, et al. Biperiden Dependence: Case Report and Literature Review. Case reports in psychiatry, 2012, 2012.
- Ferruginol
Catalog No.:BCN3155
CAS No.:514-62-5
- Euphol
Catalog No.:BCN7790
CAS No.:514-47-6
- Tirucallol
Catalog No.:BCN7787
CAS No.:514-46-5
- Parkeol
Catalog No.:BCN3728
CAS No.:514-45-4
- Periplogenin
Catalog No.:BCN2656
CAS No.:514-39-6
- Abietic acid
Catalog No.:BCN2728
CAS No.:514-10-3
- Taraxerone
Catalog No.:BCN5636
CAS No.:514-07-8
- 2-(2-Aminoethyl)-1-methylpyrrolidine
Catalog No.:BCC8477
CAS No.:51387-90-7
- Boc-Methioninol
Catalog No.:BCC2720
CAS No.:51372-93-1
- Tris DBA
Catalog No.:BCC7685
CAS No.:51364-51-3
- delta-Amyrin acetate
Catalog No.:BCN5635
CAS No.:51361-60-5
- Budesonide
Catalog No.:BCC4767
CAS No.:51333-22-3
- Canthaxanthin
Catalog No.:BCC8139
CAS No.:514-78-3
- Alrestatin
Catalog No.:BCC6663
CAS No.:51411-04-2
- Chikusetsusaponin IVa
Catalog No.:BCN3432
CAS No.:51415-02-2
- Odonicin
Catalog No.:BCN5637
CAS No.:51419-51-3
- 3-Methyladenine
Catalog No.:BCC3714
CAS No.:5142-23-4
- COG 133
Catalog No.:BCC1047
CAS No.:514200-66-9
- Cyclo(Tyr-Phe)
Catalog No.:BCN2423
CAS No.:5147-17-1
- Deoxynivalenol
Catalog No.:BCC7832
CAS No.:51481-10-8
- Cimetidine
Catalog No.:BCC4527
CAS No.:51481-61-9
- PMX 205
Catalog No.:BCC8039
CAS No.:514814-49-4
- H-Tyr(tBu)-OMe.HCl
Catalog No.:BCC2672
CAS No.:51482-39-4
- Sclareol
Catalog No.:BCN2395
CAS No.:515-03-7
Effect of Biperiden Treatment in Acute Orofacial and Extremity Dyskinesia With Methylphenidate Therapy.[Pubmed:28328695]
Pediatr Emerg Care. 2018 Nov;34(11):e217-e218.
Methylphenidate is a stimulant drug commonly prescribed to individuals with attention-deficit/hyperactivity disorder. The suggested underlying mechanism of acute dyskinesias is dopaminergic transmission increase. We describe a 9-year-old boy with a diagnosis of attention-deficit/hyperactivity disorder admitted to emergency clinic with primarily orofacial and extremity dyskinesia after administration of a first dose of 18 mg OROS (osmotic [controlled] release oral) methylphenidate (Concerta). OROS methylphenidate was discontinued, and the patient's symptoms resolved within 20 minutes after injection of Biperiden by intravenous route (0.04 mg/kg). We wish to emphasize that acute orofacial dyskinesia and extremity dyskinesia can be observed during methylphenidate therapy and that Biperiden can be successfully used in the treatment of this unpleasant condition. To the best of our knowledge, this is the first report of the use of Biperiden therapy in this condition. This case report highlights the importance for physicians of awareness of dyskinesia as a potential adverse effect of methylphenidate therapy and indicates benefit of Biperiden therapy.
The antidepressant-like effects of biperiden may involve BDNF/TrkB signaling-mediated BICC1 expression in the hippocampus and prefrontal cortex of mice.[Pubmed:28216067]
Pharmacol Biochem Behav. 2017 Jun;157:47-57.
Preclinical and clinical studies suggest that neuronal muscarinic acetylcholine receptor (M-AchR) antagonists have antidepressant-like properties. Despite the recent interest in bicaudal C homolog 1 gene (BICC1) as a target for the treatment of depression, the upstream signaling molecules that regulate BICC1 are unknown, and very few studies have addressed the involvement of BICC1 in the antidepressant-like effects of the selective M1-AchR inhibitor, Biperiden. Growing evidence indicates that activation of brain-derived neurotrophic factor (BDNF)/tropomyosin-related kinase receptor B (TrkB) signaling may be involved in antidepressant-like activities. In this study, we investigated the role of BDNF/TrkB signaling in the regulation of BICC1 expression in the chronic unpredictable stress (CUS) mouse model of depression. Furthermore, we also examined whether BDNF/TrkB signaling contributes to the antidepressant-like effects of Biperiden via down-regulation of BICC1 in the hippocampus and prefrontal cortex of mice. Our current data show that CUS exposure induced significant depression-like behaviors, down-regulation of BDNF/TrkB signaling and up-regulation of BICC1 in the hippocampus and prefrontal cortex of mice. However, Biperiden significantly alleviated the CUS-induced abnormalities. Moreover, we found that the effects of Biperiden were antagonized by pretreatment with the TrkB antagonist K252a. Our results indicate that BDNF/TrkB signaling may be the major upstream mediator of BICC1 involvement in the antidepressant-like effects of Biperiden.
Effects of biperiden and acute tryptophan depletion and their combination on verbal word memory and EEG.[Pubmed:28210777]
Psychopharmacology (Berl). 2017 Apr;234(7):1135-1143.
BACKGROUND: Research on the neurobiological foundations of memory has shown that multiple neurotransmitters play an important role in memory processing. To study the interaction between neurotransmitters such as acetylcholine and serotonin, pharmacological models can be used. In this study, we tested the effects of the muscarinic M1 antagonist Biperiden, acute tryptophan depletion (ATD), and the interaction between the two on episodic memory using the verbal learning task. METHODS: The study was conducted according to a double-blind, placebo-controlled, four-way crossover design. Seventeen participants received Biperiden (2.0 mg), ATD (SolugelP), a combination of both, or a placebo in counterbalanced order with a wash out of at least 7 days. A verbal learning task was performed while recording electroencephalography. The task consisted of an immediate and delayed recall as well as a recognition part. RESULTS: Results revealed decreased scores on the delayed recall after Biperiden and ATD separately but no significant interaction between the two. However, the event-related potential components P3b, N400, and P600 did show an interaction during encoding. CONCLUSION: These results indicate that both BIP and ATD impair episodic memory. However, an interaction between the serotonergic and cholinergic system on memory performance is not supported.
